Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | WDR5 | P61964 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | SRC | P12931 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21193586 | 0.87 | HTR6 (0.39) | KDM2BHTR6MAPTKMT2AHTR2A | |
| SCHEMBL4465337 | 0.86 | MEN1 (0.38) | MEN1ALDH1A1MAPTPKMALOX15 | |
| Hydrochloric Acid SCHEMBL15415295 | 0.84 | MEN1 (0.37) | MEN1ALDH1A1MAPTPKMALOX15 | |
| SCHEMBL14254669 | 0.75 | KDM2B (0.39) | KDM2BMEN1ALDH1A1MAPTPKM | |
| SCHEMBL3488529 | 0.75 | KDM2B (0.39) | KDM2BMEN1ALDH1A1MAPTPKM | |
| SCHEMBL8440410 | 0.75 | KDM2B (0.39) | KDM2BMEN1ALDH1A1MAPTPKM | |
| Hydrochloric Acid SCHEMBL30232427 | 0.75 | KDM2B (0.39) | KDM2BMEN1ALDH1A1MAPTPKM | |
| Hydrochloric Acid SCHEMBL1994942 | 0.75 | KDM2B (0.39) | KDM2BMEN1ALDH1A1MAPTPKM | |
| Hydrochloric Acid SCHEMBL27671598 | 0.73 | HTR6 (0.33) | KDM2BHTR6HTR2AHTR2CHTR2B | |
| SCHEMBL19732429 | 0.72 | KDM2B (0.49) | KDM2BWDR5HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2358202-B1 | BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES | MERCK SHARP & DOHME (US) | 2016-06-15 | — | — | EP | disclosed |
| EP-2358202-B1 | BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES | MERCK SHARP & DOHME (US) | 2016-06-15 | — | — | EP | disclosed |
| EP-2375904-B1 | BIARYL CARBOXAMIDES | MERCK SHARP & DOHME (US) | 2014-05-28 | — | — | EP | disclosed |
| US-8470819-B2 | Benzimidazole and aza-benzimidazole carboxamides | MERCK SHARP & DOHME CORP. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8470819-B2 | Benzimidazole and aza-benzimidazole carboxamides | MERCK SHARP & DOHME CORP. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8470819-B2 | Benzimidazole and aza-benzimidazole carboxamides | MERCK SHARP & DOHME CORP. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8367679-B2 | Biaryl carboxamides | MERCK SHARP & DOHME CORP. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367679-B2 | Biaryl carboxamides | MERCK SHARP & DOHME CORP. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367679-B2 | Biaryl carboxamides | MERCK SHARP & DOHME CORP. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20110230498-A1 | BIARYL CARBOXAMIDES | MERCK SHARP & DOHME CORP. | 2011-09-22 | — | — | US | disclosed |
| US-20110230498-A1 | BIARYL CARBOXAMIDES | MERCK SHARP & DOHME CORP. | 2011-09-22 | — | — | US | disclosed |
| US-20110230498-A1 | BIARYL CARBOXAMIDES | MERCK SHARP & DOHME CORP. | 2011-09-22 | — | — | US | disclosed |
| US-20110207750-A1 | BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES | MERCK SHARP & DOHME LLC | 2011-08-25 | — | — | US | disclosed |
| US-20110207750-A1 | BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES | MERCK SHARP & DOHME LLC | 2011-08-25 | — | — | US | disclosed |
| US-20110207750-A1 | BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES | MERCK SHARP & DOHME LLC | 2011-08-25 | — | — | US | disclosed |
| US-7713965-B2 | 7-substituted 3-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials | VETOQUINOL SA (FR) | 2010-05-11 | — | — | US | disclosed |
| US-7713965-B2 | 7-substituted 3-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials | VETOQUINOL SA (FR) | 2010-05-11 | — | — | US | disclosed |
| WO-2010051245-A1 | BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES | MERCK SHARP & DOHME CORP. (US) | 2010-05-06 | — | — | WO | disclosed |
| US-20090221565-A1 | NOVEL 7-SUBSTITUTED 3-CARBOXY-OXADIAZINO-QUINOLONE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS ANTI-BACTERIALS | VETOQUINOL SA (FR) | 2009-09-03 | — | — | US | disclosed |
| US-20090221565-A1 | NOVEL 7-SUBSTITUTED 3-CARBOXY-OXADIAZINO-QUINOLONE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS ANTI-BACTERIALS | VETOQUINOL SA (FR) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221565-A1 | NOVEL 7-SUBSTITUTED 3-CARBOXY-OXADIAZINO-QUINOLONE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS ANTI-BACTERIALS | CBR3, CBR1, TECR | KDM2B 3220/4885HTR6 2632/4885MEN1 4040/4885 |
| US-20110230498-A1 | BIARYL CARBOXAMIDES | PAFAH1B3, PAFAH1B2, FAAH2 | KDM2B 2076/4885HTR6 2835/4885MEN1 3394/4885 |
| US-20110207750-A1 | BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES | PAFAH1B3, PAFAH1B2, PAF1 | KDM2B 414/4885HTR6 3004/4885MEN1 3540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.